Longwood Valley

Longwood Valley MedTech (Longwood Valley®) is a national high-tech enterprise and a national "specialized, refined, distinctive, and innovative" Little Giant enterprise, focusing on orthopedic artificial intelligence and surgical robot solutions. It provides hospitals' orthopedic departments with comprehensive solutions, including AI-assisted diagnosis, personalized surgical planning, surgical robots, and postoperative evaluation. As an R&D-driven global leader in intelligent orthopedics innovation, the company's core R&D team comes from world-class institutions such as Harvard University, Tsinghua University, and Peking University. To date, it has achieved over 300 domestic and international patents and software copyrights, and has been repeatedly recognized as a national high-tech enterprise, a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise, a Zhongguancun High-Tech Enterprise, a Zhongguancun Eagle Talent Enterprise, a Zhongguancun Golden Seed Enterprise, a model unit for intellectual property, one of China’s Top 50 Medical Artificial Intelligence Enterprises, a 2022 Hurun Global Gazelle Enterprise, one of Fortune China’s Most Socially Influential Enterprises in 2022, one of the ten most investable enterprises by the Global Times, a 10x Growth Potential Healthcare Enterprise in China 2022 by 36Kr, a top 10 investment case in China’s best medical device sector by China Venture, a Future Healthcare 100 Strong - China Innovative Digital Healthcare List, and ranked on the Surgical Robotics Value Domain List. Currently, Longwood Valley® has completed seven rounds of financing (Series B+), with investors including top venture capital firms from China and abroad, such as IDG Capital, CDH Investments, CICC Capital, SoftBank China, Legend Capital, Legend Star, Vivo Capital, Oriza Ventures, Zhongguancun Development Group, Huajin Capital, and FreeS Fund.